<?xml version="1.0" encoding="UTF-8"?>
<ref id="cas14841-bib-0004">
 <label>4</label>
 <mixed-citation publication-type="journal" id="cas14841-cit-0004">
  <string-name>
   <surname>Yamazaki</surname>
   <given-names>K</given-names>
  </string-name>, 
  <string-name>
   <surname>Nagase</surname>
   <given-names>M</given-names>
  </string-name>, 
  <string-name>
   <surname>Tamagawa</surname>
   <given-names>H</given-names>
  </string-name>, et al. 
  <article-title>Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first‐line treatment for patients with metastatic colorectal cancer (WJOG4407G)</article-title>. 
  <source xml:lang="en">Ann Oncol</source>. 
  <year>2016</year>;
  <volume>27</volume>(
  <issue>8</issue>):
  <fpage>1539</fpage>‐
  <lpage>1546</lpage>.
  <pub-id pub-id-type="pmid">27177863</pub-id>
 </mixed-citation>
</ref>
